Cytokine Production Articles & Analysis: Older
12 news found
Creative BioMart's team of specialists were on hand to discuss how the company's products and services can support researchers in their work. They engaged with attendees, answering questions, providing product information, and exploring how Creative BioMart can help accelerate immunology research. ...
Recently, the product manager of the company was pleased to announce the launch of its Cancer Cytokines Assay, assisting in the detection of multiple cytokine levels within a single sample. ...
LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney. The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. ...
LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney. The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. ...
LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney. The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. ...
LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney. The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. ...
Study results demonstrate GBA1-targeted allosteric regulators increase GCase protein levels, reduce the production of inflammatory cytokines, and improve key lysosomal functions BETHESDA, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. ...
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products and will enable Thermo Fisher to provide customers significant benefits through an integrated offering. ...
LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney. The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. ...
LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney. The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. ...
Creative Biolabs has released a series of purified reporter-encoding OVs, including herpes simplex virus and vaccinia virus. Featured products: Reporter-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP34.5, ΔUNG), SV40-GFP Reporter-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP27), CMV-Dsred Reporter-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP27), ...
With COVID-19 heightening general awareness of inflammation and cytokines, discovering a natural product which can assist is a hugely significant finding for the team. ...